WID researcher Shaoqin Sarah Gong is working to more safely deliver a variety of drugs to treat cancer, heart disease and even blindness.
Error rates as high as 50 percent are a problem when the goal is to correct typos in the DNA that cause genetic disease. Now, a team of researchers led by WID’s Kris Saha has made the fix less mistake-prone.
In August 2017, Randolph Ashton received almost $800,000 from the National Institute of Neurological Disorders and Stroke, part of NIH, to continue a five-year research study of Lou Gehrig’s disease (amyotrophic lateral sclerosis, or ALS), after successfully completing its first phase.
The National Science Foundation has awarded nearly $20 million to a consortium of universities to support a new engineering research center that will develop transformative tools and technologies for the consistent, scalable, and low-cost production of high-quality living therapeutic cells. Several WID investigators are collaborators on the project.
The main scientific focus of the lab is in defining how the epigenome controls cell identity. We want to know how non-genetic information controls functional specialization of a cell and use this knowledge to direct efficient conversion of desired cell types with the ultimate goal of improving stem cell based therapy.
By bringing together stem cell biology, genome engineering, and biomaterials expertise, the Saha lab generates new tools for use with human-induced pluripotent stem cells to ask unique questions about human biology and disease.
Prof. Gong’s research group focuses on the design, synthesis/fabrication, and characterization of novel materials and devices. Many of their ongoing projects are multidisciplinary, bridging engineering with materials science, chemistry, and life sciences. Some of their efforts include multifunctional drug/agent nanocarriers for the combined delivery of therapeutic and diagnostic agents which can be used to treat and diagnose various types of diseases. Her group also studies multifunctional polymer nanocomposites for various applications including flexible electronics, supercapacitors, and nanogenerators.
The Turng lab works with injection molding and innovative plastics manufacturing processes (such as microcellular injection molding / MuCell process), pioneering materials (biobased polymers, nanocomposites, electro-active polymers (EAPs), etc.), and intelligent modeling and process control (computer-aided engineering (CAE), numerical simulation, design and process optimization, intelligent injection molding control, and Internet-based collaboration) to advance the science and manufacturing techniques surrounding tissue engineering scaffolds.
The Ashton Group is working to understand, model, and recapitulate in vitro the instructive signals utilized by human embryos to pattern tissue-specific differentiation of pluripotent stem cells, and apply this knowledge towards the rational design of tissue engineered scaffolds and other regenerative therapeutic strategies.
WKOW Channel 27 highlights Randolph Ashton’s NSF grant to create blank model for spinal cells.
Kris Saha illuminates the inner workings of gene editing.
Thanks to the research of Professor Lih-Sheng (Tom) Turng, plastics can have applications in products ranging from eyeglass lenses to engineered tissues.
WID scientists David Page and Bill Murphy were part of a study using stem cells to create model neural tissues to screen for toxicity.
Tools for Discovery is a monthly profile series that inspects the computer programs, gadgets and methods behind WID’s ideas and discoveries.
A WID team examines greener materials to offer a cheaper and more sustainable way to absorb oil from water.